Type of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Navigation Menu

Type of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor

Evaluating the effectiveness and safety of first-line tyrosine kinase inhibitor with or without radiotherapy for the treatment of patients with oligometastatic EGFR-mutated NSCLC.

Evaluating the effectiveness and safety of first-line tyrosine kinase inhibitor with or without radiotherapy for the treatment of patients with oligometastatic EGFR-mutated NSCLC.

Posted by on May 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of first-line tyrosine kinase inhibitors (TKIs) with or without radiotherapy (RT) for the treatment of patients with oligometastatic (OM) non-small-cell lung cancer (NSCLC) having genetic mutations in the epidermal growth factor receptor (EGFR). The data showed that TKI plus RT was safe and...

Read More

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Posted by on Jan 20, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) after surgery. The data showed that early recurrence after surgery was associated with poor survival outcomes in patients with stage IIIA-N2 NSCLC. Smoking history, large tumor size, increased lymph node ratio, and...

Read More

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Posted by on Jan 16, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The data showed that alectinib (Alecensa) and lorlatinib (Lorbrena) were the most effective and safest first-line treatment options for these patients. Some background...

Read More

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Posted by on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of trastuzumab deruxtecan (Enhertu) in patients with previously untreated metastatic HER2-mutant non-small-cell lung cancer (NSCLC). The data showed that trastuzumab deruxtecan was safe and showed strong anticancer activity in these patients. Some background NSCLC is the most common form...

Read More

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of single and double immune checkpoint inhibitors (ICI)-based treatments in patients with advanced non-small-cell lung cancer (NSCLC). The data showed that the effectiveness and safety of both single and double ICI-based treatments were similar and higher...

Read More

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the benefits of postoperative radiotherapy (PORT; radiation after surgery) in patients with resectable stage III-N2 non-small-cell lung cancer (NSCLC). The data showed that PORT significantly increased survival without disease progression and reduced the risk of cancer relapse for these patients. Some background...

Read More

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy after surgery. The data showed that EGFR-TKI therapy after surgery significantly improved survival without disease progression in...

Read More

Evaluating the effectiveness and safety of anlotinib combined with radiotherapy to the head for patients with brain metastases from NSCLC.

Evaluating the effectiveness and safety of anlotinib combined with radiotherapy to the head for patients with brain metastases from NSCLC.

Posted by on Oct 3, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of combining cranial radiotherapy (CRT; radiotherapy tot the head) with and without anlotinib (AL3818) for the treatment of patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). The data showed that anlotinib plus CRT significantly improved survival without brain...

Read More

Evaluating afatinib in patients with advanced non-small cell lung cancer who have not received EGFR TKIs

Evaluating afatinib in patients with advanced non-small cell lung cancer who have not received EGFR TKIs

Posted by on Aug 14, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of afatinib (Gilotrif) in patients with non-small cell lung cancer (NSCLC) who have not previously received EGFR tyrosine kinase inhibitors (TKIs). Data showed that afatinib was well tolerated and improved the outcomes of these patients. Some background NSCLC...

Read More

Comparing lobectomy and sublobar resection for older patients with stage 1A NSCLC

Comparing lobectomy and sublobar resection for older patients with stage 1A NSCLC

Posted by on Jul 11, 2021 in Lung cancer | 0 comments

In a nutshell The study was carried out to assess the difference in outcomes between lobectomy (LE) and sub-lobar resection (SLR) for older patients with stage I non-small-cell lung cancer (NSCLC). The authors found that both surgeries had similar outcomes in these patients.  Some background NSCLC is responsible for 85% of lung cancer diagnoses...

Read More

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Posted by on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of ceritinib (Zykadia) and alectinib (Alecensa) in patients with ALK-positive non-small-cell lung cancer (NSCLC) who previously had a crizotinib (Xalkori) treatment failure. The data showed that both ceritinib and alectinib were effective in these patients. Some background Non-small-cell lung cancer...

Read More